Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Fig. 3

Association of the change of bITH scores after ICIs plus chemotherapy with clinical outcomes. A Kaplan-Meier curve for progression-free survival (PFS) according to bITH change status. bITH up was defined as a ≥ 10% increase in bITH score from baseline, with a second confirmatory measurement after treatment. Log-rank test was used for statistical analysis. B Objective response rate (ORR) (left) and durable clinical benefit (DCB) rate (right) among bITH up and bITH stable or down. Fisher’s exact test was used for statistical analysis. C Waterfall plot of bITH score change and the maximum change in tumor size from baseline. bITH, blood-based intratumor heterogeneity; HR, hazard ratio; ORR, objective response rate; DCB, durable clinical benefit; BOR, best overall response; PD, progressive disease; SD, stable disease; PR, partial response. MSAF, maximum somatic allele frequency

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us